Tapentadol placed in schedule II in the US and filed in the EU
27 May 2009
John Davis
Please Login to read the full article.
27 May 2009
John Davis
john.davis@informa.com
Johnson & Johnson's centrally acting analgesic tapentadol is to be placed in schedule II of the Controlled Substances Act in the US, the Drug Enforcement Administration has concluded in a final rule.
The product, which was co-developed with the originator, Grünenthal, has been waiting for...
Please Login to read the full article.
RELATED CONTENT
NEWS
- BDSI CEO: Shared fentanyl REMS puts Onsolis on level playing field
- Janssen wins US FDA nod for chronic pain drug Nucynta ER
- PharmacoFore secures $10M Series B to advance "next generation" abuse resistant opioids, plus propofol alternative
- Grünenthal's Palexia SR launched in UK
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
